Valuation: Sandoz Group AG

Capitalization 35.29B 30.43B 27.47B 26.36B 48.06B 3,243B 50.3B 325B 130B 1,555B 132B 130B 5,562B P/E ratio 2026 *
27.3x
P/E ratio 2027 * 21.8x
Enterprise value 38.38B 33.09B 29.87B 28.66B 52.26B 3,527B 54.7B 353B 141B 1,691B 144B 141B 6,049B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.97x
Free-Float
95.68%
Yield 2026 *
1.22%
Yield 2027 * 1.51%
1 day-1.82%
1 week-6.67%
Current month-6.67%
1 month+3.39%
3 months+10.02%
6 months+29.87%
Current year+9.75%
1 week 62.74
Extreme 62.74
69.3
1 month 61.4
Extreme 61.4
72.7
Current year 56.94
Extreme 56.94
72.7
1 year 26.25
Extreme 26.25
72.7
3 years 22.7
Extreme 22.7
72.7
5 years 22.7
Extreme 22.7
72.7
10 years 22.7
Extreme 22.7
72.7
Manager TitleAgeSince
Chief Executive Officer 59 2018-12-31
Director of Finance/CFO 58 2024-06-30
Chief Tech/Sci/R&D Officer 59 2025-05-31
Director TitleAgeSince
Director/Board Member 63 2023-07-31
Chairman 66 2023-02-28
Director/Board Member 61 2023-07-31
Change 5d. change 1-year change 3-years change Capi.($)
-1.82%-6.67%+63.48% - 35.29B
+0.72%-5.86%+13.89%+218.81% 885B
+0.32%-3.23%+44.22%+56.01% 579B
-0.96%-0.85%+7.38%+50.47% 407B
-2.93%-7.03%+11.14%+27.55% 350B
-1.25%-5.55%+22.14%+55.83% 302B
-1.85%-6.70%+20.11%+33.64% 301B
-0.24%-6.49%+22.33%+4.06% 286B
+0.53%-4.80%+13.75%+61.56% 199B
-0.83%-3.37%+22.59%+79.29% 179B
Average -0.83%-4.89%+24.10%+65.25% 352.4B
Weighted average by Cap. -0.48%-4.61%+20.71%+89.09%

Financials

2026 *2027 *
Net sales 12.11B 10.44B 9.43B 9.04B 16.49B 1,113B 17.26B 111B 44.64B 534B 45.45B 44.48B 1,909B 12.68B 10.93B 9.87B 9.47B 17.26B 1,165B 18.07B 117B 46.72B 559B 47.57B 46.56B 1,998B
Net income 1.35B 1.16B 1.05B 1.01B 1.84B 124B 1.92B 12.41B 4.97B 59.43B 5.06B 4.95B 213B 1.64B 1.42B 1.28B 1.23B 2.24B 151B 2.34B 15.11B 6.05B 72.39B 6.16B 6.03B 259B
Net Debt 3.09B 2.66B 2.4B 2.31B 4.21B 284B 4.4B 28.41B 11.38B 136B 11.59B 11.34B 487B 2.39B 2.06B 1.86B 1.78B 3.25B 219B 3.4B 21.96B 8.8B 105B 8.96B 8.77B 376B
Logo Sandoz Group AG
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
Employees
22,356
Date Price Change Volume
26-03-06 63.48 CHF -1.82% 920,854
26-03-05 64.66 CHF -2.62% 796,650
26-03-04 66.40 CHF +1.47% 972,750
26-03-03 65.44 CHF -3.20% 1,083,589
26-03-02 67.60 CHF -0.62% 1,194,325
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
81.56USD
Average target price
81.23USD
Spread / Average Target
-0.40%

Quarterly revenue - Rate of surprise